Filing Details
- Accession Number:
- 0001415889-24-026908
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-14 20:14:19
- Reporting Period:
- 2024-10-10
- Accepted Time:
- 2024-11-14 20:14:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1870404 | Cero Therapeutics Holdings Inc. | CERO | Biological Products, (No Disgnostic Substances) (2836) | 871088814 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2042634 | Yk Bioventures Opportunities Gp I, Llc | 398 Primrose Road, Suite 328 Burlingame CA 94010 | No | No | No | No | |
| 2042636 | Yk Bioventures Opportunities Fund I, L.p. | 398 Primrose Road, Suite 328 Burlingame CA 94010 | No | No | Yes | No | |
| 2042691 | William Mitchell Kossar | C/O Yk Bioventures 398 Primrose Road, Suite 328 Burlingame CA 94010 | No | No | Yes | No | |
| 2042700 | Kahing Gary Yeung | C/O Yk Bioventures 398 Primrose Road, Suite 328 Burlingame CA 94010 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-10-10 | 3,250,000 | $0.10 | 22,620,783 | No | 4 | S | Indirect | By YK Bioventures Opportunities Fund I, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By YK Bioventures Opportunities Fund I, L.P. |
Footnotes
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.09 to $0.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.
Billionaire Hedge Funds
